Docetaxel is currently indicated for androgen-independent, metastatic prostate cancer; there is also evidence demonstrating the role of CYP1B1 in modulating the activity of the drug. We present the case of a man with residual disease after radical prostatectomy treated successfully with docetaxel chemotherapy. After only two cycles of therapy, a complete remission was obtained and then consolidated with additional cycles of docetaxel and radiotherapy. Prospective genetic analysis had shown that the patient had a favourable CYP1B1 genotype. He has been disease free since August 2006. Prospective trials investigating this strategy are warranted.
|Autori:||BRANDI G; DE ROSA F; DANESI R; MONTINI GC; BIASCO G|
|Titolo:||Durable complete response to frontline docetaxel in an advanced prostate cancer patient with favourable CYP1B1 isoforms: suggestion for changing paradigms?|
|Anno del prodotto:||2008|
|Digital Object Identifier (DOI):||10.1016/j.eururo.2008.07.029|
|Appare nelle tipologie:||1.1 Articolo in rivista|